EZB Stock Overview
A life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Enzo Biochem, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.92 |
| 52 Week High | US$1.35 |
| 52 Week Low | US$0.92 |
| Beta | 0.73 |
| 11 Month Change | -10.68% |
| 3 Month Change | -8.91% |
| 1 Year Change | -17.12% |
| 33 Year Change | -68.92% |
| 5 Year Change | -62.90% |
| Change since IPO | -98.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| EZB | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -13.2% | 0.3% | -1.3% |
| 1Y | -17.1% | 15.7% | 7.4% |
Return vs Industry: EZB underperformed the German Healthcare industry which returned 14.5% over the past year.
Return vs Market: EZB underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| EZB volatility | |
|---|---|
| EZB Average Weekly Movement | 3.9% |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EZB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: EZB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 131 | Kara Cannon | www.enzo.com |
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry.
Enzo Biochem, Inc. Fundamentals Summary
| EZB fundamental statistics | |
|---|---|
| Market cap | €49.20m |
| Earnings (TTM) | -€9.37m |
| Revenue (TTM) | €30.44m |
1.6x
P/S Ratio-5.2x
P/E RatioIs EZB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EZB income statement (TTM) | |
|---|---|
| Revenue | US$31.91m |
| Cost of Revenue | US$17.28m |
| Gross Profit | US$14.63m |
| Other Expenses | US$24.45m |
| Earnings | -US$9.82m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 45.86% |
| Net Profit Margin | -30.77% |
| Debt/Equity Ratio | 0.5% |
How did EZB perform over the long term?
See historical performance and comparisonDividends
41.2%
Current Dividend Yieldn/a
Payout RatioDoes EZB pay a reliable dividends?
See EZB dividend history and benchmarks| Enzo Biochem dividend dates | |
|---|---|
| Ex Dividend Date | Nov 15 2024 |
| Dividend Pay Date | Dec 02 2024 |
| Days until Ex dividend | 8 days |
| Days until Dividend pay date | 9 days |
Does EZB pay a reliable dividends?
See EZB dividend history and benchmarks